Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-saving medical products, has announced positive results from the first group of patients dosed with PRV-002 in its phase I clinical trial. According to the update, Odyssey’s trial is administering PRV-002, its novel drug to treat concussion, to healthy human subjects. Thus far, the drug has shown to be safe and well tolerated. “Based on our animal data and after reviewing our initial phase I trial safety reports, we are optimistic that PRV-002 will be a safe option for the treatment of concussion,” said Michael Redmond, CEO of Odyssey Health. “We look forward to completing the phase I trial and presenting our findings to the FDA. Following FDA review, we intend to initiate a phase II clinical trial in the U.S., starting with our military. We have created a military advisory board to assist with this effort.”
To view the full press release, visit https://ibn.fm/k8fpb
About Odyssey Health Inc. (formerly Odyssey Group International Inc.)
Odyssey is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey’s corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
